CHECKPOINT ATHERO: developing immune checkpoint-based therapeutics for atherosclerosis

Eur Heart J. 2023 Mar 21;44(12):1010-1012. doi: 10.1093/eurheartj/ehac793.

Authors

Esther Lutgens¹, Willem J M Mulder^{2

3}; CHECKPOINT ATHERO consortium

Collaborators

CHECKPOINT ATHERO consortium:
Esther Lutgens, Willem Mulder, Claudia Monaco, Isabel Gonçalves, Coleen McNamera, Johan Kuiper, Randolph Noelle

Affiliations

¹ Experimental CardioVascular Immunology Lab, Department of Cardiovascular Medicine, Mayo Clinic, 200 First St SW, 55905, Rochester, MN, USA.
² Department of Internal Medicine and Radboud Center for Infectious diseases (RCI), Radboud University Medical Centre, Nijmegen, the Netherlands.
³ Laboratory of Chemical Biology, Department of Biomedical Engineering, Eindhoven University of Technology, Eindhoven, the Netherlands.

PMID: 36691949
DOI: 10.1093/eurheartj/ehac793

No abstract available

Publication types

Research Support, Non-U.S. Gov't

MeSH terms

Atherosclerosis* / drug therapy
Humans
Immune Checkpoint Inhibitors* / therapeutic use

Substances

Immune Checkpoint Inhibitors

Grants and funding